Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study

(2017) Wei-Cheng Tseng et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

(2016) Gemma Currie et al.   BMC Nephrology

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

(2015) Khai P Ng et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease

(2014) Murray Epstein   Lancet Diabetes & Endocrinology

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

(2013) Ron T Gansevoort et al.   LANCET

Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease

(2013) WEISONG WANG et al.   Experimental and Therapeutic Medicine

Blood pressure has only minor influence on aldosterone-induced oxidative stress and DNA damage in vivo

(2012) Nina Queisser et al.   FREE RADICAL BIOLOGY AND MEDICINE

Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury

(2012) James M. Luther et al.   KIDNEY INTERNATIONAL

Aldosterone stimulates nuclear factor-kappa B activity and transcription of intercellular adhesion molecule-1 and connective tissue growth factor in rat mesangial cells via serum- and glucocorticoid-inducible protein kinase-1

(2011) Yoshio Terada et al.   Clinical and Experimental Nephrology

Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression

(2011) Cesar Cerezo et al.   JOURNAL OF HYPERTENSION

Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease

(2011) M. Lian et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Aldosterone-induced kidney injury is mediated by NFκB activation

(2010) Seiichi Fukuda et al.   Clinical and Experimental Nephrology

Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease

(2009) Nicola C. Edwards et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies—the effect on podocytes

(2009) Zalan Nemeth et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Aldosterone Induces Apoptosis in Rat Podocytes: Role of PI3-K/Akt and p38MAPK Signaling Pathways

(2009) Cheng Chen et al.   NEPHRON EXPERIMENTAL NEPHROLOGY

Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial

(2008) Leszek Tylicki et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Spironolactone exhibits direct renoprotective effects and inhibits renal renin–angiotensin–aldosterone system in diabetic rats

(2008) Masateru Taira et al.   EUROPEAN JOURNAL OF PHARMACOLOGY